ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1193

Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1255

Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1580

Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1503

Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1527

Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1082

Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 0985

Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1485

Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1515

Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1424

Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0956

Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics

(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1216

Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1357

Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0947

Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition

(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1511

Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].